New perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) II: Albumin suppresses Angiotensin Converting Enzyme (ACE) activity in human

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Fagyas, Miklós ^a   Úri, Katalin ^a   Siket, Ivetta M ^a   Fülöp, Gá Bor Á ^a   Csató, Viktória ^a   Daragó, Andrea ^a   Boczán, Judit ^a   Bányai, Emese ^a   Szentkirályi, István Elek ^a   Maros, Tamás Miklós ^a   Szerafin, Tamás ^a   Édes, István ^a   Papp, Zoltán ^a   Tóth, Attila ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; SERUM ALBUMIN; ACE PROTEIN, HUMAN; ANGIOTENSIN I; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RECOMBINANT PROTEIN;

ARTICLE; BINDING ASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; IMMUNOPRECIPITATION; MOLECULAR INTERACTION; NORMAL HUMAN; PROTEIN CROSS LINKING; PROTEIN FUNCTION; PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SAPHENOUS VEIN; SEROLOGY; VASOCONSTRICTION; WESTERN BLOTTING; BIOMECHANICS; BLOOD; DRUG EFFECTS; ENZYME ACTIVE SITE; ENZYMOLOGY; KINETICS; METABOLISM; MOLECULAR WEIGHT;

ANGIOTENSIN I; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOMECHANICAL PHENOMENA; CATALYTIC DOMAIN; HUMANS; KINETICS; MOLECULAR WEIGHT; PEPTIDYL-DIPEPTIDASE A; RECOMBINANT PROTEINS; RENIN-ANGIOTENSIN SYSTEM; SAPHENOUS VEIN; SERUM ALBUMIN;

EID: 84898663585     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087844     Document Type: Article

References (37)

1. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327: 669-677.
2. Corvol P, Michaud A, Soubrier F, Williams TA (1995) Recent advances in knowledge of the structure and function of the angiotensin I converting enzyme. J Hypertens Suppl 13: S3-10.
3. Hubert C, Houot AM, Corvol P, Soubrier F (1991) Structure of the angiotensin I-converting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene. J Biol Chem 266: 15377-15383. (Pubitemid 21907658)
4. Oppong SY, Hooper NM (1993) Characterization of a secretase activity which releases angiotensin-converting enzyme from the membrane. Biochem J 292 (Pt 2: 597-603.
5. Wei L, Alhenc-Gelas F, Soubrier F, Michaud A, Corvol P, et al. (1991) Expression and characterization of recombinant human angiotensin I-converting enzyme. Evidence for a C-terminal transmembrane anchor and for a proteolytic processing of the secreted recombinant and plasma enzymes. J Biol Chem 266: 5540-5546. (Pubitemid 21909527)
6. Fox KM (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362: 782-788.
7. Hoogwerf BJ, Young JB (2000) The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not. Cleve Clin J Med 67: 287-293. (Pubitemid 30219953)
8. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, et al. (1995) Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 91: 2573-2581.
9. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, et al. (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart. Eur Heart J 33: 1787-1847.
10. Taylor J (2012) Joint societies CVD Prevention Guidelines launched in May 2012. Eur Heart J 33: 1539. doi:10.1093/eurheartj/ehs137.
11. Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, et al. (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevatio. Eur Heart J 32: 2999-3054.
12. Tendera M, Aboyans V, Bartelink M-L, Baumgartner I, Clément D, et al. (2011) ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatm. Eur Heart J 32: 2851-2906.
13. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, et al. (2010) Guidelines on myocardial revascularization. Eur Heart J 31: 2501-2555.
14. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, et al. (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28: 88-136. (Pubitemid 46137814)
15. Wald NJ, Law MR (2003) A strategy to reduce cardiovascular disease by more than 80%. BMJ 326: 1419.
16. Ryan JW, Martin LC, Chung A, Pena GA (1979) Mammalian inhibitors of angiotensin converting enzyme (kininase II). Adv Exp Med Biol 120B: 599-606.
17. Snyder RA, Wintroub BU (1986) Inhibition of angiotensin-converting enzyme by des-Leu10-angiotensin I: a potential mechanism of endogenous angiotensinconverting enzyme regulation. Biochim Biophys Acta 871: 1-5. (Pubitemid 16064518)
18. Rogerson FM, Livett BG, Scanlon D, Mendelsohn FA (1989) Inhibition of angiotensin converting enzyme by N-terminal fragments of substance P. Neuropeptides 14: 213-217. (Pubitemid 20032937)
19. Ikemoto F, Song GB, Tominaga M, Yamamoto K (1989) Endogenous inhibitor of angiotensin converting enzyme in the rat heart. Biochem Biophys Res Commun 159: 1093-1099. (Pubitemid 19101094)
20. Lieberman J, Sastre A (1986) An angiotensin-converting enzyme (ACE) inhibitor in human serum. Increased sensitivity of the serum ACE assay for detecting active sarcoidosis. Chest 90: 869-875. (Pubitemid 17196178)
21. Brecher AS, Thevananther S, Wilson S (1996) Observation of high and low molecular weight inhibitors of angiotensin-converting enzyme in rat lung. Arch Int Pharmacodyn Ther 331: 301-312. (Pubitemid 27026457)
22. Thevananther S, Brecher AS (1999) Isolation of angiotensin converting enzyme (ACE) binding protein from human serum with an ACE affinity column. Can J Physiol Pharmacol 77: 216-223. (Pubitemid 29342845)
23. Fagyas M, Úri K, Mányiné IS, Daragó A, Boczán J, et al. (2014) New perspectives in the renin-angiotensin- aldosterone system (RAAS) I: endogenous angiotensin converting enzyme (ACE) inhibition. PLoS One. doi:10.1371/journal.pone.0087843.
24. Beneteau B, Baudin B, Morgant G, Giboudeau J, Baumann FC (1986) Automated kinetic assay of angiotensin-converting enzyme in serum. Clin Chem 32: 884-886. (Pubitemid 17028376)
25. Carmona AK, Schwager SL, Juliano MA, Juliano L, Sturrock ED (2006) A continuous fluorescence resonance energy transfer angiotensin I-converting enzyme assay. Nat Protoc 1: 1971-1976. (Pubitemid 46773320)
26. Davidson NC, Barr CS, Struthers AD (1996) C-type natriuretic peptide. An endogenous inhibitor of vascular angiotensin-converting enzyme activity. Circulation 93: 1155-1159. (Pubitemid 26089807)
27. Tauzin J, Miclo L, Gaillard JL (2002) Angiotensin-I-converting enzyme inhibitory peptides from tryptic hydrolysate of bovine alphaS2-casein. FEBS Lett 531: 369-374. (Pubitemid 35341226)
28. León-Ruiz V, González-Porto AV, Al-Habsi N, Vera S, San Andrés MP, et al. (2013) Antioxidant, antibacterial and ACE-inhibitory activity of four monofloral honeys in relation to their chemical composition. Food Funct.
29. Nakagomi K, Fujimura A, Ebisu H, Sakai T, Sadakane Y, et al. (1998) Acein-1, a novel angiotensin-I-converting enzyme inhibitory peptide isolated from tryptic hydrolysate of human plasma. FEBS Lett 438: 255-257. (Pubitemid 28529284)
30. Nakagomi K, Ebisu H, Sadakane Y, Fujii N, Akizawa T, et al. (2000) Properties and human origin of two angiotensin-I-converting enzyme inhibitory peptides isolated from a tryptic hydrolysate of human serum albumin. Biol Pharm Bull 23: 879-883. (Pubitemid 30484389)
31. Klauser RJ, Robinson CJ, Marinkovic DV, Erdös EG (1979) Inhibition of human peptidyl dipeptidase (angiotensin I converting enzyme: kininase II) by human serum albumin and its fragments. Hypertension 1: 281-286.
32. Fagyas M, Úri K, Mányiné IS, Daragó A, Boczán J, et al. (2014) New perspectives in the renin-angiotensin- aldosterone system (RAAS) III: endogenous inhibition of angiotensin converting enzyme (ACE) provides protection against cardiovascular diseases. PLoS One.
33. Howard G, Downward G, Bowie D (2001) Human serum albumin induced hypotension in the postoperative phase of cardiac surgery. Anaesth Intensive Care 29: 591-594. (Pubitemid 33138612)
34. Cushman DW, Cheung HS (1971) Concentrations of angiotensin-converting enzyme in tissues of the rat. Biochim Biophys Acta - Enzymol 250: 261-265.
35. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlöf B, et al. (2001) The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 88: 1L-20L. (Pubitemid 33022712)
36. Van Dijk MA, Kroon I, Kamper AM, Boomsma F, Danser AH, et al. (2000) The angiotensin-converting enzyme gene polymorphism and responses to angiotensins and bradykinin in the human forearm. J Cardiovasc Pharmacol 35: 484-490. (Pubitemid 30127198)
37. Úri K, Fagyas M, Mányiné IS, Kertész A, Csanádi Z, et al. (2014) New perspectives in the renin-angiotensin- aldosterone system (RAAS) IV: Circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure. PLoS One.